Blade Therapeutics, a biopharmaceutical company, and Biotech Acquisition, a SPAC, terminated its $352m merger. Investors in PIPE included Deerfield Management, Pfizer Ventures, Bristol Myers Squibb, MPM Capital and Osage University Partners. "We wish Blade continued success as they continue to develop cutting-edge science and a clinical-stage pipeline targeting diseases that remain undertreated. BAC remains committed to finding a life-sciences partner that can deliver value for our shareholders," Michael Shleifer, BAC Chairman and CEO.